No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence: Very Low
Coadministration with twice daily raltegravir has not been studied. Population PK analysis showed emtricitabine/tenofovir-DF had minimal effect on the pharmacokinetics of once daily raltegravir (12% increase in relative bioavailability). Coadministration of tenofovir-DF and raltegravir (400 mg twice daily) increased raltegravir AUC (49%) and Cmax (64%), but had no effect on Cmin; tenofovir AUC, Cmax and Cmin decreased by 10%, 23% and 13%, respectively. The safety profile observed in patients who used atazanavir and/or tenofovir-DF (both agents that increase raltegravir concentrations) was generally similar to that of patients who did not use these agents. No clinically significant interaction is expected with emtricitabine. No dose adjustment is required when coadministered with twice daily or once daily raltegravir.